Janney Montgomery Scott’s Harvard Bioscience HBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,108
Closed -$6K 2755
2025
Q1
$6K Hold
1,108
﹤0.01% 2662
2024
Q4
$23K Hold
1,108
﹤0.01% 2670
2024
Q3
$30K Hold
1,108
﹤0.01% 2628
2024
Q2
$32K Hold
1,108
﹤0.01% 2570
2024
Q1
$47K Buy
1,108
+8
+0.7% +$360 ﹤0.01% 2683
2023
Q4
$59K Hold
1,100
﹤0.01% 2577
2023
Q3
$47K Hold
1,100
﹤0.01% 2519
2023
Q2
$60K Hold
1,100
﹤0.01% 2587
2023
Q1
$46K Sell
1,100
-600
-35% -$17.8K ﹤0.01% 2412
2022
Q4
$47K Hold
1,700
﹤0.01% 2516
2022
Q3
$44K Hold
1,700
﹤0.01% 2455
2022
Q2
$62K Hold
1,700
﹤0.01% 2277
2022
Q1
$106K Hold
1,700
﹤0.01% 2171
2021
Q4
$120K Hold
1,700
﹤0.01% 2299
2021
Q3
$119K Hold
1,700
﹤0.01% 2228
2021
Q2
$142K Hold
1,700
﹤0.01% 2182
2021
Q1
$93K Hold
1,700
﹤0.01% 2130
2020
Q4
$73K Hold
1,700
﹤0.01% 2196
2020
Q3
$51K Hold
1,700
﹤0.01% 2037
2020
Q2
$53K Buy
+1,700
New +$45.8K ﹤0.01% 1955
2015
Q2
Sell
-1,055
Closed -$61K 2084
2015
Q1
$61K Buy
+1,055
New +$56.7K ﹤0.01% 2341

Other funds holding HBIO

Janney Montgomery Scott's HBIO Position: Q2 2025 in Review

Janney Montgomery Scott sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 1,108 shares — an estimated $6K sold.

Janney Montgomery Scott first reported a position in HBIO in Q1 2015 and held it in 21 quarters. The position peaked at $142K in Q2 2021. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

  • Janney Montgomery Scott reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
  • Janney Montgomery Scott sold 1,108 Harvard Bioscience shares in Q2 2025, an estimated $6K.
  • Janney Montgomery Scott first reported a position in Harvard Bioscience in Q1 2015 and held it in 21 quarters.
  • Janney Montgomery Scott's Harvard Bioscience position peaked at $142K in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on Janney Montgomery Scott's 13F filing for Q2 2025, filed 17 Jul 2025.